Abstract | Spondyloarthritis (SpA) is a term that refers to a group of inflammatory diseases that includes psoriatic arthritis, axial SpA and nonradiographic axial SpA , reactive arthritis, enteropathic arthritis and undifferentiated SpA. The disease subtypes share clinical and immunological features, including joint inflammation (peripheral and axial skeleton); skin, gut and eye manifestations; and the absence of diagnostic autoantibodies (seronegative). The diseases also share genetic factors. The aetiology of SpA is still the subject of research by many groups worldwide. Evidence from genetic, experimental and clinical studies has accumulated to indicate a clear role for the IL-17 pathway in the pathogenesis of SpA. The IL-17 family consists of IL-17A , IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, of which IL-17A is the best studied. IL-17A is a pro-inflammatory cytokine that also has the capacity to promote angiogenesis and osteoclastogenesis. Of the six family members, IL-17A has the strongest homology with IL-17F. In this Review , we discuss how IL-17A and IL-17F and their cellular sources might contribute to the immunopathology of SpA.
). As we discuss later in this Review, IL-17A was initially described as a product of CD4 + T cells (Box 2) but is now known to be produced by CD8 + 
T cells, γδ T cells, natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells and a range of other immune cells.
The expression of IL-17A is regulated by inflammatory cytokines. Specifically, the relationship between IL-23 and IL-17 has led to the concept of the IL-23-IL-17 axis as a pivotal pathway contributing to host protection and inflammation 2, 3 (Box 2; Fig. 1 ).
IL-17A has been implicated in the immunopathology of several inflammatory diseases, including inflammatory arthritis (reviewed elsewhere 3, 4 ) , and its effector function has been extensively studied. IL-17A signalling in IL-17 receptor-bearing target cells (Box 3), including fibroblasts, epithelial cells and synoviocytes, results in the transcription of pro-inflammatory genes, leading to the secretion of a range of pro-inflammatory cytokines (including IL-6, TNF and IL-1) 5 , T cell-attracting and myeloid cell-attracting chemokines (CC-chemokine ligand 20 (CCL20), CCL2 and CCL7) 6, 7 and neutrophilic granulocyte-attracting chemokines (CXC-chemokine ligand 1 (CXCL1), CXCL2, CXCL5 and CXCL8) 5, 8 .
Additionally, IL-17A increases the production and secretion of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in stromal cells, macrophages and T cells, thereby increasing granulopoiesis 9 . IL-17A also regulates production of antimicrobial peptides (defensins and S100 proteins) by IL-17 receptor-bearing target cells 10 . Although IL-17A has an important role in inflammation and host protection against specific pathogens, excessive activation of this pathway can contribute to autoimmunity or chronic inflammatory disease. In the context of inflammatory arthritis, IL-17A can induce the production of matrix metalloproteinases (MMPs) (MMP1, MMP9 and MMP13) from target cells, thereby driving the degradation of extracellular matrix within the joint 11, 12 . Furthermore, IL-17A can upregulate receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL; also known as TNFSF11) expression by osteo blasts, which can subsequently lead to osteoclast activation and bone destruction 13 . IL-17A also promotes angiogenesis, thus increasing blood flow and facilitating the influx of inflammatory cells into the inflamed joint 14, 15 . Several reports have shown that IL-17F functions in a similar manner to IL-17A, albeit with less potency; the literature describes a hierarchy in inflammatory potential with IL-17A homodimers eliciting the strongest inflammatory response, followed by IL-17A-IL-17F heterodimers and then IL-17F homodimers 16 . IL-17F has
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Leonie S. Taams   1 been shown to upregulate pro-inflammatory mediators including IL-6, CXCL1, CXCL8, GM-CSF, CCL2, CCL7 and MMP13 in fibroblasts and epithelial cells 17, 18 . Furthermore, IL-17F has been linked to neutrophilia in the context of severe asthma 19 . These experimental data demonstrate the potent pro-inflammatory, osteoclastogenic and angiogenic capacity of IL-17A and/or IL-17F and suggest that these cytokines are critical drivers of inflammation. In this Review, we consider evidence from genetic studies, experimental models, in vitro experiments and clinical studies that implicate the IL-23-IL-17 axis and the cells that produce IL-17, in particular CD8 + T cells, in the immunopathogenesis of spondyloarthritis (SpA).
The evolving concept of SpA
In 1859, Garrod distinguished immune-mediated inflammatory arthritis from gout and tuberculous arthritis 20, 21 . Clinical pattern recognition remained paramount in identifying arthritis subtypes until the discovery of rheumatoid factor 22 provided a pathological basis for the division of seropositive and seronegative arthritis groups. Ankylosing spondylitis (AS), which primarily affects the spine, was recognized as a specific clinical entity in 1973, with reports of a strong relationship with the HLA-B27 genotype confirming a different genetic basis for AS from that of rheumatoid arthritis (RA) 23, 24 . Peripheral seronegative arthritis was less well defined until the recognition of overlapping clinical features with the skin condition psoriasis; Moll and Wright thus coined the term psoriatic arthritis (PsA) in 1963 (reF.
25
). The Classification for Psoriatic Arthritis (CASPAR) criteria were subsequently developed in 2006 (reF. 26 ). The overlapping clinical, immunological and genetic characteristics of the 'seronegative arthritides' led to the suggestion that these conditions could be considered a single entity called SpA, including axial SpA (axSpA) (extending the former definition of AS to include those identified by nonradiographic means), PsA, enteropathic arthritis, reactive arthritis and undifferentiated SpA, with a combined population prevalence of 1-2% 27, 28 . These conditions all have differing components of peripheral and axial (spine and sacroiliac joint) arthritis, enthesitis, dactylitis, uveitis, inflammatory bowel disease (IBD) and psoriasis or psoriasiform skin involvement 29 . The non-articular disease components, such as psoriasis or Crohn's disease, can be the dominant manifestation of these diseases. The broadening of the definition of SpA reflects increasing awareness of nonrheumatoid inflammatory arthritis as well as the impact of new imaging modalities.
Role of IL-17 family members in SpA
Although the mechanisms underlying SpA pathogenesis have not been completely elucidated, evidence suggests a clear role for the IL-23-IL-17 axis in this process. In the following section, we discuss the association of genetic variants in the major histocompatibility complex (MHC) class I pathway and the IL-23-IL-17 axis with susceptibility to SpA. We briefly review the role of IL-23-IL-17 in animal models of inflammatory arthritis and discuss data regarding the presence of IL-17 family members in the blood and tissues of patients with SpA. Finally, we discuss how IL-17 could promote joint inflammation and disrupt bone homeostasis by synergizing with other pro-inflammatory cytokines.
Genetics of SpA with a focus on the MHC class I pathway and the IL-23-IL-17 axis. Although some evidence suggests the involvement of MHC class II in AS 30 , the strongest association with genetic susceptibility to SpA lies within the MHC class I region. To date, the HLA-B27 region represents the strongest genetic risk association identified in axSpA, PsA and reactive arthritis [31] [32] [33] , and positivity for HLA-B27 is strongly associated with sacroiliitis in both AS and PsA. In addition, multiple other variants within the MHC class I loci are associated with PsA (including HLA-B39, HLA-Cw6, HLA-B38 and HLA-B08) or AS (HLA-A02 and HLA-B07), with some associations most evident when patients are stratified by clinical characteristics 30, [34] [35] [36] . The association of SpA with a variety of different HLA-B loci indicates that several immunological mechanisms could be altered by these genetic associations, including T cell repertoire selection and antigen presentation 37 . Given that MHC class I molecules present peptides to CD8 + T cells, this genetic association suggests that CD8 + T cells are implicated in SpA. Initially, variants in the HLA-B27 region were thought to contribute to disease susceptibility through direct presentation of an arthritogenic peptide to cytotoxic CD8 + T cells 38 . Alternative data suggest that variants within this locus promote HLA-B27 homodimerization instead of heterodimerization with β 2 -microglobulin 39 or that HLA-B27 protein misfolding occurs, activating the unfolded protein response and increasing IL-23 production 40, 41 . Finally, HLA-B27 homodimers bind with increased affinity to killer cell immunoglobulinlike receptor 3DL2 (KIR3DL2), which is expressed on IL-17 + CD4 + T cells from the blood and synovial fluid of patients with AS 42 . These data suggest a link between MHC class I and the IL-23-IL-17 axis.
In addition to the HLA region, variants in the ERAP1/2 loci, which encode enzymes required for HLA class I peptide trimming) [43] [44] [45] , and the RUNX3 locus, which encodes runt-related transcription factor 3, a transcription factor essential for CD8 + T cell development and differentiation [46] [47] [48] , are associated with AS and PsA as well as psoriasis [49] [50] [51] [52] . 45, 49, 56, 57, 59 . In patients with AS, susceptibility variants in the IL23R locus are associated with altered transcript levels of genes related to the T helper 1 (T H 1) cell and/or T H 17 cell response, including IL17A and RORC
60
. These data suggest the involvement of IL-23 in the development of SpA. Interestingly, SpA and Behçet syndrome have several overlapping genetic associations (for example, variants in IL23R, ERAP1 and HLA class I genes), indicating that these 'MHC-I-opathies' may have similar underlying immunopathology 61 . As IL-23 is known to be important for sustained IL-17 production, it is interesting that additional susceptibility variants associated with inflammatory diseases have been identified in genes encoding IL-23-IL-17-related signalling molecules including TYK2, TRAF3IP2 and STAT3. Variants in the TYK2 locus, encoding a tyrosine kinase required for IL-23 signalling, are associated with AS, PsA and IBD 52, 56, 59 . Variants in TRAF3IP2 (which encodes NF-κB activator 1 (ACT1; also known as TRAF3IP2) are associated with PsA, psoriasis and IBD 50, 52, 59 . ACT1 is a key ubiquitin ligase required for IL-17 signalling through the IL-17 receptor complex and subsequent induction of the NF-κB pathway 62 (Box 3). Furthermore, genotyping studies have shown a suggestive association between STAT3 and AS 63, 64 and PsA 65 . Signal transducer and activator of transcription 3 (STAT3) is a transcription factor induced upon IL-23 (as well as IL-6 and IL-21) signalling in CD4 + T cells and is a main regulator of the differentiation and function of IL-17-producing CD4 + T cells 66, 67 . Finally, studies have reported genetic associations with TNFAIP3 (which encodes TNFα-induced protein 3) and/or TNIP1 (which encodes TNFAIP3-interacting protein 1) in psoriasis 68 , PsA 52 and IBD
59
, with a suggestive association for AS 69 . TNFAIP3 is an anti-inflammatory, ubiquitin-modifying enzyme that can dampen NF-κB-mediated inflammation and that has been implicated in multiple autoimmune and inflammatory conditions; TNFAIP3 restrains IL-17 signalling in stromal cells 70 . TNIP1 is a critical factor controlling IL-17 biology in non-haematopoietic cells (keratinocytes and fibroblasts) both in vivo and in vitro 71 . Figure 2 is a hypothetical depiction of how susceptibility genes associated with SpA might influence both CD8 + T cell-related and CD4 + T cell-related IL-23-IL-17-mediated immune responses.
IL-17 in animal models of SpA.
A key role of IL-17-dependent and IL-23-dependent pathways has been shown in many inflammatory arthritis models, including the early models said to represent RA and those developed to model aspects of SpA. The adjuvant-induced arthritis model, which uses arthritis-prone rat strains and the potent adjuvant Complete Freund's Adjuvant, is T cell-dependent, lacks autoantibodies and produces a resolving destructive inflammatory peripheral arthritis, osteitis and ankylosis of the tail 72 . The first demonstration that inhibiting IL-17A in an animal model reduced disease activity and joint damage was reported in this model 73 . Furthermore, collagen-induced arthritis (CIA), the archetypal model for RA, cannot be induced in IL-17 or IL-17 receptor knockout animals [74] [75] [76] ; development of arthritis in this model is dependent on IL-17 in the early phases and partly suppressed by IL-17A inhibition during the active inflammatory phase. Conversely, overexpression of IL-17 with adenoviral vectors exacerbates CIA severity and joint destruction 77 . In the streptococcal cell wall model of inflammatory arthritis, prevention of IL-17 signalling blocks transition from transient arthritis to persistent arthritis after repeated inoculations 78 . A comprehensive review of animal models of pathogenic SpA pathways classified the models into related groups of HLA-B27 overexpression, TNF overexpression, IL-23-dependence and curdlan-induced arthritis in SKG mice 79 . Studies of mechanisms of HLA-B27 overexpression in rats demonstrated expansion of IL-17 + CD4 + T cells 40, 80 , whereas a role for CD8 + T cells was not supported 81, 82 . The SKG mouse, which has a tyrosine-protein kinase ZAP70 T cell receptor defect, develops arthritis and autoantibodies in response to a natural fungal lung infection; this model was originally described as a model for RA 83 . However, specific pathogen-free mice injected • Il-17A was first identified in 1993 through a subtractive hybridization screen of a rodent T cell library (then referred to as cytotoxic T lymphocyte antigen 8, CTlA8) 1 ( Fig. 1 ). Subsequent work detected IL17A mRNA in a human CD4 + T cell clone 5, 214 .
• Proteomic and genomic database searches led to the discovery of the remaining Il-17 family members, Il-17B, Il-17C, Il-17D, Il-17e and Il-17F, all of which display a degree of similarity in amino acid sequence to Il-17A [215] [216] [217] .
• using nested rapid amplification of cDNA ends (RACe) PCR, Il-17F was cloned first, bearing the strongest (50%) homology to Il-17A. The IL17F gene was found to be located adjacent to IL17A on chromosome 6p12, and expression of Il-17F was observed in activated CD4 + T cells 217 .
• Both Il-17A and Il-17F can be secreted as homodimers.
In addition, mouse and human studies have identified an Il-17A-Il-17F heterodimer 16, 218 .
with fungal derivatives develop different features, with downstream effects on SpA-associated genes. A detailed study of this model revealed many SpA features, including gut and skin inflammation and uveitis, followed by autoantibody formation 84 . IL-23 mediates the effects on local mucosal dysregulation and the production of cytokines driving the SpA syndrome, including IL-17-dependent arthritis and IL-22-dependent enthesitis 85 . Enthesitis precedes joint inflammation in the CIA model 86 , and the introduction of exogenous IL-23 by mini-circle DNA implants results in increased enthesitis. This process is mediated by IL-17 produced by IL-23R + CD3 + CD4 -CD8 -lymphoid cells resident at the enthesis 87 . Finally, certain mouse strains spontaneously develop a dermatitis resembling psoriasis and joint ankylosis as they age, and important roles of IL-17 have been described in these models particularly in the early stages of the disease 88, 89 .
Presence of IL-17A and IL-17F cytokines in SpA.
Several studies have reported increased IL-17 production or increased IL17 mRNA expression in the serum, synovial fluid or tissue of patients with RA compared with patients with osteoarthritis (OA) and healthy individuals, indicating the presence of IL-17 in immunemediated arthritis 13, 15, [90] [91] [92] [93] [94] . IL-17 has also been detected in the serum or synovial fluid of patients with early RA, suggesting its importance in disease initiation 94, 95 . Compared with RA, fewer studies have focused on SpA; however, IL-17 and/or IL-23 levels are substantially higher in serum from patients with SpA (consisting of AS, reactive arthritis and/or undifferentiated SpA) than in age and sex-controlled healthy individuals 96, 97 . In patients with AS, serum levels of IL-17 positively correlated with disease activity, as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 98, 99 . Regarding the site of inflammation, higher levels of IL-17 have been detected in the synovial fluid than in the serum of patients with PsA 91 and in the synovial fluid of patients with reactive arthritis or undifferentiated SpA than in the synovial fluid of patients with OA or RA 100 . Furthermore, flow cytometry and western blot analysis revealed higher IL-17 receptor A (IL-17RA) expression in synoviocytes from patients with PsA (and RA) than in OA synoviocytes 101 . An intestinal biopsy study described upregulation of IL23A (which encodes the p19 subunit) transcripts in the terminal ileum of patients with AS, suggesting that the gut is an important source of IL-23 in AS; however, upregulation of IL17 mRNA was not observed in the same samples 102 . Synergistic effects of IL-17A and IL-17F. IL-17A can exert potent synergistic effects in the presence of other cytokines and mediators to augment pro-inflammatory responses, which could contribute to rheumatic disease. Although few studies have investigated the synergistic effects of IL-17A in the context of SpA, the literature on RA and experimental in vitro and in vivo systems is extensive, providing valuable insight into the synergistic function of IL-17A and its potential role in SpA (Fig. 3) . One of the best-studied synergies is IL-17A with TNF. Reports show that IL-17A can synergize with TNF to induce increased production of pro-inflammatory mediators such as IL-6, IL-8 and CCL20 from RA synoviocytes 103, 108, 109 . The synergy between IL-17A and TNF increases granulopoiesis by inducing increased levels of GM-CSF in RA synoviocytes 108 and G-CSF from human epithelial cells 110 . Moreover, IL-17A can combine with TNF to exhibit synergistic effects on the induction of CCL2 and CXCL2 from mouse mesangial cells 111 . In a CIA mouse model, IL-17A and TNF overexpression in synovial tissue from knee joints results in increased joint inflammation and cartilage erosion; this process is associated with a synergistic increase in expression of protein S100A8 (an alarmin associated with cartilage destruction), IL-1β and MMPs
112
. Similarly, IL-17A and TNF synergistically increase levels of S100A8 in the antigen-induced arthritis mouse model 113 and increase MMP2 and CXC-chemokine receptor 4 (CXCR4) expression by RA synoviocytes, leading to an increase in cell invasion, as examined by transwell Matrigel invasion chambers 114 .
As previously mentioned, IL-17 can contribute to bone destruction by inducing production of RANKL and the induction of osteoclastogenesis. This destructive effect can be exacerbated in the presence of TNF. In the synovial membrane, mRNA levels of both IL17A and TNF are predictive of rapid joint damage progression in RA, particularly in patients with shorter disease duration 115 . In an RA ex vivo bone explant model, the inhibitory effect of TNF blockade on collagen degradation was increased when combined with IL-17 and IL-1 blockade 116 . In addition, a study of TNF transgenic mice demonstrated that dual IL-17 and TNF blockade was more effective at restoring bone homeostasis than blockade of IL-17 or TNF alone; combined IL-17 and TNF inhibition led to decreased osteoclast and increased osteoblast numbers, increased osteocalcin levels and a reduction in RANKL levels, all of which contributed to protection from bone resorption 117 . Whereas systemic bone loss can occur in both RA and SpA, a characteristic feature of SpA is ectopic bone formation. The exact roles of inflammatory cytokines in new bone formation are still incompletely understood (reviewed elsewhere 118 ). IL-17 can enhance the effects of TNF on bone matrix formation by mesenchymal stem cells (MSCs) 119 . These cytokines can synergistically increase the mineralization of the MSC extracellular matrix, which is a marker of human MSC differentiation into osteoblasts. Alkaline phosphatase (ALP), an enzyme produced by MSCs that is essential for bone mineralization, is increased in the presence of IL-17 and TNF, whereas MSC RANKL expression is substantially downregulated 119 . However, further studies are required to determine the paradoxical effects of IL-17A and TNF on bone destruction and formation (Fig. 3) .
In addition to TNF, IL-17A has been shown to synergize with other pro-inflammatory cytokines including IL-1β and IFNγ. The combination of IL-17A and IL-1β increases IL-6 production by RA synoviocytes 120 and increases CCL20 production by fibroblast-like synoviocytes 121 .
In the CIA mouse model, blocking both IL-17A and IL-1β reduces cartilage degradation and bone destruction and downregulates the expression of IL-1β, IL-6, IFNγ, RANKL and MMP3 in cartilage tissue 122 . Moreover, a bispecific antibody for IL-17A and IL-1β improves clinical signs of CIA in mice compared with blocking IL-17A or IL-1β alone 123 . IL-17A and IFNγ synergistically upregulate IL-6 and IL-8 production by keratinocytes and lead to a subtle increase in expression of intercellular adhesion molecule 1 (ICAM1), a ligand that binds leukocyte adhesion glycoprotein LFA-1 α-chain (LFA-1A; also known as ITGAL) on T cells to cause T cell adhesion to keratinocytes 124 . This mechanism could augment inflammation in diseases of the skin, such as psoriasis.
Similar to IL-17A, IL-17F can synergize with other cytokines, amplifying its inflammatory potential. Realtime RT-PCR analysis revealed that IL-17F synergizes with TNF to augment IL6, IL8 and CXCL5 mRNA levels from RA synoviocytes. Although the combination of IL-17A and TNF induces a higher fold increase in levels of mRNA for pro-inflammatory cytokines than IL-17F and TNF, the effect of IL-17F and TNF synergy is potent 103 . IL-17F can also synergize with TNF to induce elevated levels of G-CSF from human epithelial cells 110 and synergizes with both TNF and IL-1β, increasing the expression of CCL2 and CXCL2 from mouse mesangial cells 111 . Although studies have demonstrated the proinflammatory capability of IL-17F, it remains to be firmly established that IL-17F contributes to the immunopathology of SpA; robust evidence confirming the presence and function of IL-17F in SpA is still lacking. However, if IL-17F is present, it has the potential to contribute to SpA pathology; reports suggest that IL-17F is not redundant with IL-17A and that dual blockade of these cytokines can further reduce inflammation 
cells (T helper 17 (T H 17) cells) as a distinct CD4
+ T cell lineage separate from T H 1 cells and T H 2 cells 219, 220 (Fig. 1 ).
• T H 17 cell differentiation is dependent on signals from Il-6, transforming growth factor β (TGFβ), Il-1β and Il-21, whereas Il-23 is important for lineage maintenance [221] [222] [223] [224] [225] [226] . Il-23 has also been shown to contribute to the pathogenicity of T H 17 cell subsets 219, 227 .
• The main regulator of T H 17 cells is the transcription factor retinoid-related orphan receptor-γ (RoRC) 228 . other transcription factors that contribute to T H 17 cell differentiation include RoRα, signal transducer and activator of transcription 3 (STAT3), interferon regulatory factor 4 (IRF4) and aryl hydrocarbon receptor (AHR) 66, [229] [230] [231] [232] .
• In addition to Il-17A and Il-17F, T H 17 cells can produce an array of other cytokines including IFNγ, TNF, granulocyte-macrophage colony-stimulating factor, Il-21, Il-22, Il-9 and Il-10. The presence and expression levels of these cytokines depend on the cytokine milieu present upon T H 17 cell polarization [233] [234] [235] [236] [237] , and they may synergize with or antagonize Il-17 function 233, 235, 236, 238 . compared with blockade of IL-17A alone. In a mouse model of colitis, combined blockade of IL-17A and IL-17F was more effective at ameliorating disease than blockade of IL-17A alone 125 . Moreover, dual neutralization of IL-17A and IL-17F might have a more profound effect on reducing T H 17 cell culture supernatant-induced IL-8 and IL-6 production by synoviocytes from patients with PsA and healthy human dermal fibroblasts than inhibition of IL-17A or IL-17F alone 107 . The mechanisms underlying the synergy of IL-17A and IL-17F with other cytokines remain to be fully elucidated; however, the synergistic effect might occur through the ability of IL-17A to stabilize mRNA transcripts. The IL-17A and TNF synergistic increase in IL-8 protein and gene expression has been shown to be the result of IL-17A extending the half-life of the unstable TNF-induced IL8 mRNA 126 (Fig. 3) . Given that cells pretreated with a p38 mitogen-activated protein kinase (MAPK) inhibitor displayed an increased IL8 mRNA decay rate after stimulation with IL-17A and TNF, IL-17A-induced mRNA stabilization is proposed to be a p38 MAPK-dependent pathway 126 . The importance of ACT1 in IL-17A-induced stabilization has also been highlighted 8 , and other mRNA transcripts including MIP2 and CSF2 (which encodes GM-CSF) whose half-lives were extended in response to IL-17A have been identified, implicating this as a common mechanism for IL-17A synergy. To date, no studies have investigated the ability of IL-17F to stabilize mRNA transcripts. The synergistic effect of IL-17A and TNF might also be mediated by phospholipase D enzymes, which upregulate cytokine secretion 127 ; inhibition of these enzymes in vitro in RA fibroblasts that are cultured with IL-17A and TNF leads to decreased production of IL-6, IL-8 and CCL20 (reF.
127
). + CD4 + T cell percentages from the synovial fluid and levels of C-reactive protein (CRP), erythrocyte sedimentation rate, fibrinogen, synovial fluid neutrophil count and synovial fluid total leukocyte count were also reported in a cohort of patients diagnosed with RA, SpA, undifferentiated SpA, reactive arthritis, microcrystal arthritis, gout and pseudogout 140 .
IL-17-producing T cells in SpA

IL-17
+ CD8 + T cells in SpA. Evidence is increasing that CD8 + T cells are another cellular source of IL-17 (reviewed elsewhere 128 ). An initial study reported IL17 mRNA expression by human CD8 + T cell clones isolated from skin lesions of patients with psoriasis 124 ( Fig. 1) . To date, the presence of IL-17 + CD8 + T cells has been shown in multiple immune-mediated inflammatory diseases such as psoriasis, multiple sclerosis and PsA 134, [141] [142] [143] [144] . An elegant study showed that IL-17 + CD8 + T cells are enriched in the epidermis of human psoriatic skin lesions and that neutralizing anti-CD8 mono clonal antibody treatment of mice xenotransplanted with human psoriatic skin resulted in complete blockade of psoriasis development 145 . In SpA, IL-17 + CD8 + T cells are present in the peripheral blood of patients with AS, with the highest frequencies of these cells observed in patients with severe disease 146 . Furthermore, within the inflammatory joint, increased frequencies of IL-17 + CD8 + T cells are detected in the synovial fluid of patients with PsA or AS compared with peripheral blood from the same patients 134, 138 . In PsA, this enrichment correlated with markers of disease activity such as the results of power Doppler ultrasonography and CRP levels 134 . Extensive immuno phenotyping of IL-17 + CD8 + T cells from the synovial fluid of patients with SpA indicates • Il-17RA is ubiquitously expressed at particularly high levels by haematopoietic cell types, whereas Il-17RC is preferentially expressed by non-haematopoietic cells 240 .
• As Il-17A and Il-17F require Il-17RA and Il-17RC to exert their effects, these cytokines typically act on fibroblasts, epithelial cells and endothelial cells
.
• Although the binding affinities of Il-17A and Il-17F for Il-17RC are comparable, research has shown a higher affinity of Il-17A for Il-17RA than Il-17F 218, 241 .
• A conserved region known as the similar expression of fibroblast growth factor genes and Il-17 receptors (SeFIR) domain is located at the carboxy terminus of all Il-17 receptors. upon Il-17 stimulation, the cytosolic protein nuclear factor-κB (NF-κB) activator 1 (ACT1; which is encoded by TRAF3IP2) is recruited to the Il-17 complex through homotypic interactions of the SeFIR domain 242, 243 .
• ACT1 serves as both a signalling adaptor, recruiting TNF receptor-associated factor 6 (TRAF6) proteins, and an e3 ligase, mediating the ubiquitylation of TRAF6. This process leads to the activation of the canonical NF-κB pathway and the mitogen-activated protein kinase (MAPK) pathway 242, 243 .
• A unique TRAF6-independent signalling pathway involves ACT1-dependent recruitment of TRAF2 and TRAF5, and this pathway mediates Il-17A-dependent mRNA stabilization (reviewed elsewhere 242, 243 ).
that these cells have pro-inflammatory potential 147 . Notably, although frequencies of IL-17 + CD8 + T cells are increased in the inflamed joints of patients with SpA, this enrichment has not been observed in the synovial fluid of patients with RA 134 . Thus, IL-17 + CD8 + T cells might specifically contribute to the pathogenesis of HLA class I-associated SpA but not to HLA class II-associated RA. T cells that do not re-circulate through the peripheral blood and lymphoid tissues 148, 149 . Originally described in mice 150 , T RM cells are found in barrier tissues such as the lung, gut, skin, liver and genital tract 148, 151, 152 and have the potential to express IL-17A 152, 153 . Characterized by expression of markers CD69 and/or CD103 (also known as ITGAE), T RM cells are retained within tissue after activation, inducing a local inflammatory response through production of cytokines and cytotoxic mediators (reviewed elsewhere 154 ). The transcription factor RUNX3 has been described as a key regulator of T RM cell differentiation and homeostasis in mice 155 . Presently, very few human studies have described T RM cells in patients with immune-mediated inflammatory diseases, IL-17A can synergize with TNF, leading to increased production of pro-inflammatory mediators including IL-6, IL-8, CC-chemokine ligand 20 (CCL20) and CXC-chemokine ligand 1 (CXCL1). Although the mechanisms of IL-17A and TNF synergy are not yet fully understood, it has been reported that IL-17A can extend the half-life of unstable TNF-induced IL8 mRNA via p38 mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) activator 1 (ACT1)-dependent pathways. The subsequent elevated levels of IL-8, IL-6 and CCL20 recruit neutrophils and lymphocytes, leading to an enhanced inflammatory response. The combination of IL-17A and TNF has also been reported to exacerbate disruption of bone homeostasis. These cytokines can augment the upregulation of receptor activator of NF-κB ligand (RANKL) on osteoblasts and fibroblasts. Subsequently , osteoclast precursor cells expressing receptor activator of NF-κB (RANK) are differentiated into activated osteoclasts that mediate bone degradation. Conversely , IL-17A and TNF can augment ectopic bone formation by increasing mesenchymal stem cell (MSC) differentiation into osteoblasts via mineralization of the MSC extracellular matrix. This process is associated with increased alkaline phosphatase (ALP) levels and decreased RANKL expression. Differentiated osteoblasts can then deposit new bone tissue. However, further studies are required to determine the paradoxical effects of IL-17A and TNF on bone destruction and formation. T H 17 , T helper 17.
although CD8
+ T RM cells have been described in both healthy and psoriatic skin, in which T RM cells express several cytokines including IFNy, IL-17A and IL-22 (reFs 144, 152, 156, 157 
IL-17
+ MAIT cells have also been identified at higher frequencies within the peripheral blood of patients with AS than in the peripheral blood of healthy controls 164, 165 .
Invariant natural killer T cells.
To date, little evidence exists for the presence of IL-17-producing invariant NKT cells in SpA. One mouse study reported lower incidence and disease severity of induced arthritis in NKT-cell-deficient Jα281 -/-mice than in B6 mice 166 . NKT cells were found to produce IL-17; Jα281 -/-splenocytes produced little IL-17 compared with B6 splenocytes. In addition, a lower proportion of T H 17 cells was observed in Jα281 -/-mice than in B6 mice, suggesting that NKT cells maintain or activate T H 17 cells, which can contribute to inflammatory disease.
γδ T cells. γδ T cells are a subset of T cells that combine typical features of adaptive T cells (antigen recognition via T cell receptors and pleiotropic effector functions)
with an ability to respond in a rapid, innate-like manner. These cells are present in the blood but predominantly reside in specific tissues. IL-17-expressing γδ T cells were initially described in patients with psoriasis, in whom the reduced percentage of variable domain-γ (Vγ)9Vδ2 T cells in the peripheral blood was attributed to an increase in cell trafficking to the inflamed skin 167 . Subsequently, the frequency of IL-17A-expressing γδ T cells was reported to be increased in the peripheral blood of patients with PsA, AS, reactive arthritis and enthesis-related JIA compared with healthy controls [168] [169] [170] . IL-17A + γδ T cells are also enriched in the synovial fluid compared with the peripheral blood of patients with PsA, reactive arthritis or undifferentiated SpA 170, 171 . In mice, IL-23-responsive dermal γδ T cells secrete IL-17A, IL-17F and IL-22 and are implicated as key producers of IL-17A during psoriatic skin inflammation [172] [173] [174] . In a mouse model of SpA, retinoid-related orphan receptor-γ (RORC) + IL-17A-expressing γδ T cells accumulate in the enthesis, aortic root and eye, which are tissue sites commonly affected by SpA 175 .
Other cellular sources of IL-17 in SpA. In addition to T cells, other non-T cell subsets have been identified as sources of IL-17. Increased levels of IL-17-producing group 3 innate lymphoid cells (ILC3s), a lineage-negative cell population, have been identified in the peripheral blood of patients with PsA compared with healthy controls, the levels of which correlate with disease activity 
CD56
+ NK cells, which are found at higher levels in the peripheral blood of patients with enthesitis-related arthritis than in healthy controls 169 . Increased levels of IL-17-producing NK cells have also been identified in the synovial fluid in comparison with peripheral blood of patients with reactive arthritis or undifferentiated SpA 171 . Immunofluorescence microscopy on synovial tissue from patients with SpA showed co-localization of tryptase-positive cells, identified as mast cells, and IL-17 + cells, suggesting the presence of IL-17-producing mast cells in SpA 178 . However, further studies demonstrated that mast cells do not synthesize IL-17 but rather capture, store and release bioactive exogenous IL-17A 179 .
IL-23-IL-17-targeted therapies in SpA
Targeted therapies using cytokine-specific monoclonal antibodies provide some of the most compelling evidence for the important roles of specific cytokine pathways in disease pathogenesis 180 . Studies investigating IL-23-IL-17-directed therapies have helped define the complexities of these pathways in SpA and related conditions such as psoriasis and IBD 181 . Ustekinumab, which targets the p40 subunit shared by both IL-12 and IL-23, was the first agent to show superior efficacy over TNF inhibitors in patients with psoriasis [182] [183] [184] , albeit with less efficacy than TNF inhibitors in PsA 185, 186 . High doses of this drug are also effective in Crohn's disease 187 . Anti-IL-17A-directed therapies, initially secukinumab and then ixekizumab, have yielded outstanding responses in psoriasis, which have changed expectations of therapy; PASI90 (an improvement of 90% or more with respect to baseline Psoriasis Area and Severity Index score) and almost clear or clear responses occur in many patients, showing superiority to etanercept, adalimumab and ustekinumab [188] [189] [190] [191] [192] [193] . Both secukinumab and ixekizumab have shown efficacy in PsA. Secukinumab is also licensed for AS, with arthritis responses similar to those for TNF inhibitor therapy [194] [195] [196] [197] [198] [199] but with no effect in uveitis 200 . In contrast to ustekinumab, IL-17 inhibition with secukinumab or ixekizumab is associated with low levels of exacerbation of IBD, demonstrating that IL-17A has a complex role 201 . Brodalumab, which is directed at IL-17RA and thereby blocks IL-17A, IL-17C, IL-17E and IL-17F signalling, has shown good efficacy in psoriasis and PsA [202] [203] [204] but causes exacerbation of Crohn's disease 205 . Bimekizumab, a bifunctional antibody that blocks both IL-17A and IL-17F, has demonstrated good efficacy in a proof-of-concept study in 39 patients with PsA 107 , although randomized head-to-head studies are required to clarify whether dual IL-17A and IL-17F blockade is superior to IL-17A alone (as discussed above).
Specific inhibition of IL-23 by monoclonal antibodies targeting the IL-23 p19 component has shown excellent efficacy in psoriasis, with response levels at least the same as for IL-17A inhibitors. Guselkumab, now licensed for psoriasis 206, 207 , has also shown efficacy in a phase II study of PsA 208, 209 ; tildrakizumab has demonstrated efficacy in a phase III study of psoriasis, and risankizumab has shown efficacy in phase II studies in psoriasis and Crohn's disease [210] [211] [212] . These clinical data help our understanding of the complex biological effects of IL-23-IL-17 pathways in SpA and related conditions. Data from skin and synovial tissue samples from patients with psoriasis and PsA, showing more extensive IL-17-related activation networks in skin versus synovial sites 213 , might explain the difference in outcome of IL-17A inhibition in psoriasis versus PsA. Likewise, the differential responses of IL-23 versus IL-17A inhibition in Crohn's disease shows the complex role of IL-17A in the gut; furthermore, other effects of IL-23, such as IL-22 induction, might have an additive role.
Conclusions
The clinical, genetic and experimental evidence for a pathogenic role of IL-17A in SpA is compelling. In particular, the profound clinical efficacy of several drugs that target the IL-23-IL-17 pathway unequivocally demonstrates the contribution of this pathway in SpA. Importantly, IL-17A is not a sole contributor to SpA pathogenesis but acts in synergy with several other cytokines to drive the production of numerous additional pro-inflammatory and tissue-modifying mediators. As is the case in other complex, immune-mediated inflammatory diseases, SpA is probably the result of a combination of different factors culminating in imbalanced immune reactivity. The genetic evidence in SpA indicates the involvement of certain gene variants that might affect peptide presentation (MHC class I genes and ERAP1/2), alter CD8 + T cell development or differentiation (RUNX3) and/or promote increased IL-23 and/or IL-17 production (IL23, IL23R and STAT3) or IL-23-IL-17 signalling (TYK2 and TRAF3IP2) . Notably, targeted therapy using anti-cytokine monoclonal antibodies generally means that the targeted cytokine is inhibited regardless of the cellular source(s). The genetic and experimental evidence presented in this Review indicates that IL-17 + CD8 + T cells might be an important contributing source of IL-17A in SpA; however, these cells are not the only source of IL-17A. Whether IL-17 production by different cellular sources results in differential immunopathological effects remains to be established; these different effects could include, for example, differential cytokine coexpression leading to synergistic versus antagonistic effects, differences in migratory versus tissue-resident capacity by the IL-17-producing cell, coexisting cytotoxic potential or as yet unknown factors. A detailed understanding of the cellular source(s) and molecular regulation of IL-17 in SpA might open up novel avenues to specifically intervene in the production of this cytokine and thus help to ameliorate disease. 
